CStone Pharmaceuticals Completes Enrollment of First Patient in Global Multicenter Phase 1b Clinical Trial of CS5001

On December 19, 2024 CStone Pharmaceuticals (stock code: 2616.HK), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer drugs, reported that the first patient has been successfully enrolled in the global multi-center Phase 1b clinical trial of CS5001 (ROR1 ADC), a key product in its 2.0 pipeline (Press release, CStone Pharmaceauticals, DEC 19, 2024, View Source [SID1234656224]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, CS5001 has demonstrated a favorable safety profile and significant anti-tumor activity across 10 dose cohorts in a Phase 1a dose-escalation trial. CS5001 has been well-tolerated in patients with multiply pretreated advanced B-cell lymphoma and solid tumors, with no dose-limiting toxicities (DLTs) observed across all 10 dose cohorts. At the initially selected Phase II recommended dose (RP2D) of 125 μg/kg, CS5001 achieved ORRs of 70% and 100% in advanced B-cell non-Hodgkin’s lymphoma and Hodgkin’s lymphoma, respectively . Furthermore, significant efficacy signals have been observed in advanced solid tumors such as non-small cell lung cancer and pancreatic cancer.

Dr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, said, "This year, the clinical results of CS5001 have been presented at numerous international conferences and have garnered widespread attention within the industry. The latest clinical data demonstrate that CS5001 monotherapy achieves a higher ORR than competing agents in both aggressive and indolent advanced lymphomas, and the efficacy data have stabilized with increasing patient enrollment. Therefore, we believe CS5001 has the potential for accelerated registration and marketing, as well as the potential to impact the frontline combination therapy landscape . We are very pleased to see the initiation of a Phase 1b dose optimization and expansion trial of CS5001, which is expected to be further expanded into a Phase 2, single-arm, registration-enabling trial in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) . Concurrently, we will continue to explore the safety and efficacy of CS5001 in Phase 1b, either as a monotherapy or in combination with frontline standard therapies, across a variety of hematologic malignancies and solid tumors, with the goal of bringing innovative therapies with even greater survival benefits to cancer patients worldwide."

About the CS5001 (ROR1 ADC)

CS5001 is an antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). CS5001 features a unique design, utilizing a tumor-specifically activated pyrrolobenzodiazepine (PBD) protoxin payload and a linker. CS5001 is delivered only after tumor cell internalization. Within the lysosome, the linker is cleaved by a specific enzyme highly expressed in tumor cells, releasing the PBD protoxin, which is then activated and killed within the tumor cell. This "dual-control" mechanism of linker plus protoxin effectively mitigates the toxicity issues associated with traditional PBD payloads, resulting in a wider safety window. CS5001 has demonstrated complete tumor inhibition in several preclinical cancer models and exhibits favorable serum half-life and pharmacokinetic properties. All of this indicates that CS5001 has significant clinical development potential and broad application prospects in a variety of solid tumors and hematological malignancies. Furthermore, CS5001 utilizes directed conjugation technology to achieve a precise drug-antibody ratio (DAR), facilitating homogeneous production and large-scale production.

In October 2020, CStone Pharmaceuticals and LigaChem Biosciences, Inc. (LCB) entered into a licensing agreement for the development and commercialization of CS5001. CS5001 was originally synthesized by LCB and ABL bio, two leading Korean biotech companies. Under the terms of the agreement, CStone Pharmaceuticals obtained exclusive development and commercialization rights for CS5001 worldwide, excluding Korea.

Data from the first-in-human study of CS5001 in patients with advanced solid tumors and lymphomas were presented as a poster at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. Furthermore, updated clinical data on CS5001 as a monotherapy for advanced lymphomas were recently presented at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762

On December 19, 2024 Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company that develops therapeutics using its INTASYL siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cells. Phio reported that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma (Press release, Phio Pharmaceuticals, DEC 19, 2024, View Source [SID1234649220]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this Phase 1b clinical study with PH-762, dosed intratumorally, the second cohort had enrolled 4 patients who were diagnosed with cutaneous squamous cell carcinoma. At Day 36 (tumor excision), the first two patients who completed treatment showed a complete response (100% tumor clearance and a partial response 90% clearance), respectively. Pathology data assessing efficacy data on the remaining 2 patients is forthcoming.

The intratumoral injections have been well tolerated. There have been no dose-limiting toxicities, or serious adverse events in participants receiving intratumoral PH-762.

"Safety and efficacy data from our clinical trial continues to be encouraging as we develop PH-762 for the treatment of cutaneous carcinomas" said Mary Spellman MD, Phio’s acting Chief Medical Officer. "We look forward to continued enrollment in the clinical study."

CStone Pharmaceuticals Completes Enrollment of First Patient in Global Multicenter Phase 1b Clinical Trial of CS5001

On December 19, 2024 CStone Pharmaceuticals (stock code: 2616.HK), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer drugs, reported that the first patient has been successfully enrolled in the global multi-center Phase 1b clinical trial of CS5001 (ROR1 ADC), a key product in its 2.0 pipeline (Press release, CStone Pharmaceauticals, DEC 19, 2024, View Source [SID1234656224]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To date, CS5001 has demonstrated a favorable safety profile and significant anti-tumor activity across 10 dose cohorts in a Phase 1a dose-escalation trial. CS5001 has been well-tolerated in patients with multiply pretreated advanced B-cell lymphoma and solid tumors, with no dose-limiting toxicities (DLTs) observed across all 10 dose cohorts. At the initially selected Phase II recommended dose (RP2D) of 125 μg/kg, CS5001 achieved ORRs of 70% and 100% in advanced B-cell non-Hodgkin’s lymphoma and Hodgkin’s lymphoma, respectively . Furthermore, significant efficacy signals have been observed in advanced solid tumors such as non-small cell lung cancer and pancreatic cancer.

Dr. Jianxin Yang, CEO, President of R&D, and Executive Director of CStone Pharmaceuticals, said, "This year, the clinical results of CS5001 have been presented at numerous international conferences and have garnered widespread attention within the industry. The latest clinical data demonstrate that CS5001 monotherapy achieves a higher ORR than competing agents in both aggressive and indolent advanced lymphomas, and the efficacy data have stabilized with increasing patient enrollment. Therefore, we believe CS5001 has the potential for accelerated registration and marketing, as well as the potential to impact the frontline combination therapy landscape . We are very pleased to see the initiation of a Phase 1b dose optimization and expansion trial of CS5001, which is expected to be further expanded into a Phase 2, single-arm, registration-enabling trial in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) . Concurrently, we will continue to explore the safety and efficacy of CS5001 in Phase 1b, either as a monotherapy or in combination with frontline standard therapies, across a variety of hematologic malignancies and solid tumors, with the goal of bringing innovative therapies with even greater survival benefits to cancer patients worldwide."

About the CS5001 (ROR1 ADC)

CS5001 is an antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). CS5001 features a unique design, utilizing a tumor-specifically activated pyrrolobenzodiazepine (PBD) protoxin payload and a linker. CS5001 is delivered only after tumor cell internalization. Within the lysosome, the linker is cleaved by a specific enzyme highly expressed in tumor cells, releasing the PBD protoxin, which is then activated and killed within the tumor cell. This "dual-control" mechanism of linker plus protoxin effectively mitigates the toxicity issues associated with traditional PBD payloads, resulting in a wider safety window. CS5001 has demonstrated complete tumor inhibition in several preclinical cancer models and exhibits favorable serum half-life and pharmacokinetic properties. All of this indicates that CS5001 has significant clinical development potential and broad application prospects in a variety of solid tumors and hematological malignancies. Furthermore, CS5001 utilizes directed conjugation technology to achieve a precise drug-antibody ratio (DAR), facilitating homogeneous production and large-scale production.

In October 2020, CStone Pharmaceuticals and LigaChem Biosciences, Inc. (LCB) entered into a licensing agreement for the development and commercialization of CS5001. CS5001 was originally synthesized by LCB and ABL bio, two leading Korean biotech companies. Under the terms of the agreement, CStone Pharmaceuticals obtained exclusive development and commercialization rights for CS5001 worldwide, excluding Korea.

Data from the first-in-human study of CS5001 in patients with advanced solid tumors and lymphomas were presented as a poster at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. Furthermore, updated clinical data on CS5001 as a monotherapy for advanced lymphomas were recently presented at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.

Unleashing the potential of Immuno-oncology therapies

On December 19, 2024 Xilio therapeutics presented its corporate presentation (Presentation, Xilio Therapeutics, DEC 19, 2024, View Source [SID1234649221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

On December 19, 2024 Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, reported a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (Press release, Pyxis Oncology, DEC 19, 2024, View Source [SID1234649222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types. Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR) based on RECIST 1.1 criteria, including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.

Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC), and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed including patients who had previously progressed on taxanes. The data supports further development in both monotherapy and combination therapy expansion trials, including a frontline HNSCC study in combination with pembrolizumab, with patient dosing in both the monotherapy and combination therapy trials expected to begin in early 2025.

The portfolio prioritization further supports a robust development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, as well as pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer. Preliminary data from these cohorts is expected across both the second half of 2025 and the first half of 2026.

Details on the PYX-201 Phase 1 dose-escalation trial and preliminary data presented in November are available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website at ir.pyxisoncology.com.

Pipeline Prioritization

Pyxis Oncology’s second clinical program, PYX-106 — a fully human IgG1 monoclonal antibody targeting Siglec-15 — is being deprioritized to allocate resources toward advancing the lead asset, PYX-201. As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.

To date, the Phase 1 monotherapy trial of PYX-106 enrolled 45 patients with advanced solid tumors. PYX-106 was observed as generally safe and well-tolerated across all tested doses, ranging from 0.5 mg/kg to 22.5 mg/kg. At this time, a maximum tolerated dose has not been established. The pharmacokinetic and pharmacodynamic results demonstrated dose-proportional pharmacokinetics, a half-life of 9 to 11 days, no detection of antidrug antibodies in a variety of heavily pretreated solid tumors across tested dose levels.

"Deprioritizing the PYX-106 clinical program as a monoclonal antibody represents a strategic and judicious use of our resources, allowing us to focus on advancing PYX-201," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "We are excited about the potential of PYX-201, an innovative, first-in-concept ADC uniquely designed to target the tumor extracellular matrix. The positive preliminary PYX-201 Phase 1 data we presented last month reinforces our confidence in the promise of this program, particularly in addressing unmet needs in HNSCC in both monotherapy and combination therapy settings."